NCT03602820View on ClinicalTrials.gov

Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2)

Active, not recruitingOBSERVATIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

January 31, 2030

Study Completion Date

January 31, 2030

Conditions
Inherited Retinal Dystrophy Due to RPE65 Mutations
Interventions
BIOLOGICAL

AAV2-hRPE65v2

All Listed Sponsors
lead

Spark Therapeutics, Inc.

INDUSTRY

NCT03602820 - Long-term Follow-up Study in Subjects Who Received Voretigene Neparvovec-rzyl (AAV2-hRPE65v2) | Biotech Hunter | Biotech Hunter